Sagimet Biosciences Inc. Series A Common Stock (SGMT)

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated stea…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

16

Website

sagimet.com/

Fundamentals

1-day range

$10.47$10.81

Market cap

$441.53M

P/E (trailing)

—

P/E (forward)

-7.66

EPS (trailing)

$-1.34

Dividend yield

—

Beta

3.59

Avg. volume

1.22M

Forecasts

10 analyst ratings

Sagimet Biosciences Inc. Series A Common Stock Competitors

Chosen by industry and closest market cap.

• SGMT

  Sagimet Biosciences Inc. Series A Common Stock

  $10.55

  ▼ 1.86%
  Market cap $441.53MP/E —
  $4.5$11.15
• PRTA

  Prothena Corporation plc Ordinary Shares

  $9.35

  ▲ 2.86%
  Market cap $436.10MP/E —
  $7.73$11.8
• QTTB

  Q32 Bio Inc. Common Stock

  $15.01

  ▼ 7.06%
  Market cap $451.37MP/E 15.71
  $1.62$23.57
• BNTC

  Benitec Biopharma Inc. Common Stock

  $12.51

  ▼ 1.30%
  Market cap $417.41MP/E —
  $9.85$16.76
• KMDA

  Kamada Ltd. Ordinary Shares

  $8.29

  ▲ 0.36%
  Market cap $417.07MP/E 20.65
  $6.5$9.35
• LRMR

  Larimar Therapeutics Inc. Common Stock

  $4

  ▼ 1.23%
  Market cap $413.45MP/E —
  $2.72$6.42
• EOLS

  Evolus Inc. Common Stock

  $8.89

  ▲ 0.06%
  Market cap $398.42MP/E —
  $3.86$9.12

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
  benzinga · 8/25/2026
• Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29
  Benzinga · 8/14/2026
• Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56
  Benzinga · 8/12/2026
• Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) Estimate
  Benzinga · 8/11/2026
• Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026
  SeekingAlpha · 8/5/2026

• George Kemble · August 11, 2026 · Option Exercise

  10.5K @ $6.36
• George Kemble · August 11, 2026 · Option Exercise

  9.8K @ $6.36
• George Kemble · August 11, 2026 · Sale

  20.2K @ $9.95
• David Happel · July 20, 2026 · Sale

  64.1K @ $7.76
• Elizabeth Rozek · July 20, 2026 · Sale

  10.5K @ $7.76
• George Kemble · July 20, 2026 · Sale

  18.8K @ $7.46
• Hoelscher Paul W. · June 12, 2026 · Grant

  39.6K
• Jennifer Jarrett · June 12, 2026 · Grant

  39.6K
• George Kemble · June 12, 2026 · Grant

  39.6K
• Phillips Anne M. · June 12, 2026 · Grant

  39.6K
• GRAMMER ELIZABETH A · June 12, 2026 · Grant

  39.6K
• Beth C. Seidenberg · June 12, 2026 · Grant

  39.6K
• Thierry Chauche · May 28, 2026 · Grant

  50.0K
• Grauer Andreas · May 28, 2026 · Grant

  35.0K
• Elizabeth Rozek · May 28, 2026 · Grant

  100.0K

Institutional Ownership

March 31, 2026

Total shares held

13.59M

Total value held

$69.85M

Institutional holders

84